Impact of HER2 ‐low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR‐positive/HER2‐negative metastatic breast cancer: A prospective study
ConclusionThis study suggested that HER2-low expression may predict the efficacy of ET but not that of CDK4/6 inhibitor plus ET in HR-positive/HER2-negative MBC patients. The results of this study highlight the importance of integrating HER2 status in tailoring personalized treatment strategies for HR-positive MBC.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Yun Wu,
Hongnan Mo,
Hangcheng Xu,
Yan Wang,
Jiayu Wang,
Fei Ma,
Binghe Xu Tags: ORIGINAL ARTICLE Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | HER2 | Statistics | Study | Women